Laurent ARTHAUD

About Laurent ARTHAUD

Laurent Arthaud is a French executive and board member with a strong track record in life sciences, venture investing and innovation financing. He has served on Cellectis’ Board of Directors since 2011, where he contributes governance expertise, capital-markets discipline and strategic oversight. At Cellectis, a clinical-stage biotechnology company focused on gene editing and cell and gene therapies, his role is associated with independent supervision and long-term value creation. Since 2012, Arthaud has been Managing Director of Life Sciences and Ecotechnologies at Bpifrance Investissement. From 2006 to 2012, he served as Deputy CEO of CDC Entreprises. These positions show a career built around supporting high-growth innovative companies, structuring financing rounds and evaluating technology-driven investment opportunities. His experience is particularly relevant in sectors such as biotech and healthcare, where development timelines are long, capital needs are substantial and regulatory constraints are significant. Arthaud holds degrees from École Polytechnique and ENSAE Paris, giving him a combination of engineering rigor and quantitative financial analysis. That background is well suited to companies operating at the intersection of science, technology and industrial execution. In a company like Cellectis, where governance must balance scientific ambition, financing strategy and execution risk, this profile is especially valuable. Beyond Cellectis, he has served on the boards of several life sciences companies, including Sparing Vision, Kurma Life Sciences, Aledia, Ribogenics, Enyo Pharma and ArgoBio, and he was also a board member of Adocia until 2022. These mandates reflect his deep familiarity with biotech growth, fundraising, partnerships and board-level governance. Overall, Arthaud stands out as an experienced investor-director who supports innovative companies through strategic guidance, disciplined capital allocation and long-term board stewardship.